When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation

Bagnasco, Diego; Aloè, Teresita; Sclifò, Francesca; Ferrantino, Matthew; Marugo, Fiorenza; Arcadipane, Francesca; Manfredi, Andrea; Canonica, Giorgio Walter; Passalacqua, Giovanni

doi:10.23822/eurannaci.1764-1489.88

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Discontinuation of mepolizumab worsens asthma control and increases the risk of acute asthma exacerbations. 9 , 10 Another possibility may be a dose reduction. However, with missing substantial data for clinical outcomes after dose reduction of mepolizumab on one hand, and the impracticability of a reduced dose administration in the increasing use of patient self-administration with prefilled autoinjectors on the other hand, this does not seem a promising approach.…”

Section: Introductionmentioning

confidence: 99%

Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma

Bölke

Tong²,

Zuberbier³

et al. 2022

World Allergy Organization Journal

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma

Bölke

Tong²,

Zuberbier³

et al. 2022

World Allergy Organization Journal

View full text Add to dashboard Cite

Biologicals for severe asthma: what we can learn from real-life experiences?

Bagnasco

Caminati

Passalacqua

2020

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review Severe asthma is a serious disease affecting about 5–10% of asthmatic patients. Often patients with this kind of asthma requires periodical courses or daily intake of oral corticosteroids, to control symptoms. In the last few years several biological drugs have been developed with the aim to decrease exacerbations and reduce or suspend intake of systemic steroids in severe asthmatic patients. Clinical trials demonstrated the efficacy and the safety of biological antibodies in asthma, but it is already known that randomized controlled trials alone are not sufficient to provide complete information on a drug. Recent findings After marketing of monoclonal antibodies has been developed several real-life studies with the aim to observe how drugs, tested only on trial patients, are able to provide adequate effectiveness even on ‘real’ patients; indeed, it is well known that the latter differ in some characteristics from the patients of the trials. Summary The results of this analysis confirm the good efficacy of the biologics similarly in real-life patients, also ensuring a promising safety even in periods of observation longer than those of the randomized controlled trials.

show abstract